Evaxion announces pricing of $10.8 million public offering
(NASDAQ:EVAX), COPENHAGEN, Denmark, January 30, 2025 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology(TM) powered vaccines, today announced the pricing of a public offering of an aggregate of 3,997,361 of its American Depositary Shares (“ADSs”) and warrants to purchase up to 50% of the ADSs offered at a […]